A. Sikiö

Teriparatide treatment complicated by malignant myeloma

A. Koski, T. Forslund, A. Sikiö, 2010, BMJ Case Reports.

Malignant Myeloma in a Patient After Treatment for Osteoporosis with Teriparatide; a Rare Coincidence

A. Koski, T. Forslund, A. Koistinen, 2008, Clinical medicine. Case reports.

A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma

E. Jantunen, T. Siitonen, T. Selander, 2015, Bone Marrow Transplantation.

Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study

E. Jantunen, T. Siitonen, P. Mäntymaa, 2021, Transfusion.

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group

E. Jantunen, T. Siitonen, P. Mäntymaa, 2019, Annals of Hematology.

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

T. Luukkaala, T. Lundán, K. Remes, 2013, British journal of haematology.

IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence.

J. Anttinen, T. Forslund, A. Sikiö, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Impact of the number of cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery and survival in myeloma patients after autologous stem cell transplantation: Experience from the GOA study

E. Jantunen, T. Siitonen, P. Mäntymaa, 2022, Journal of clinical apheresis.

CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non‐Hodgkinʼs lymphoma patients: results of the prospective multicenter GOA study

E. Jantunen, T. Siitonen, P. Mäntymaa, 2020, Transfusion.

RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

I. Vastrik, E. Jantunen, T. Siitonen, 2016 .

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

H. Nahi, A. Waage, M. Hansson, 2020 .